Gold Nest Life Science I Portfolio Companies
A Gold Nest Life Science I Portfolio Company
Dynamic Biosensors
Enabling Technology
- High throughput label-free biosensor for drug development and diagnostics
- switchSENSE® - superior performance for multi-specific, nucleic acid, low affinity measurement and beyond
- cellTrap® - enabling kinetic measurement on live cells
A Gold Nest Life Science I Portfolio Company
BiosanaPharna
Therapeutics & Enabling Technology
- Fully continuous, small footprint and high yield manufacturing process for biologic drugs
- Reducing mAb manufacturing cost by up to 90%
- Proprietary mAb pipeline for validation of manufacturing process
A Gold Nest Life Science I Portfolio Company
Mimetas
Enabling Technology
- OrganoPlate® patented Organ-on-a-Chip
- Microfluidic 3D cell/tissue culture technology
- Phenotypic disease models that better mimic human disease conditions accelerate drug development
EMBL Ventures Portfolio Companies
An EMBL Ventures Portfolio Company
Bufferfly Network
Enabling Technology
IPO via SPAC on NYSE
- Portable smartphone-connected ultrasound system
- Democratize healthcare by making medical imaging accessible to everyone around the world
An EMBL Ventures Portfolio Company
Jiff
Others
Acquired by Castlight Health
- Health benefits platform designed for enterprises
- Help companies lower healthcare costs and cultivate happier, healthier employees
An EMBL Ventures Portfolio Company
Decipher Biosciences
Enabling Technology
Acquired by Veracyte
- RNA biomarker-based stratification testing for prostate cancer
- Predicts likelihood of metastases and cancer-specific mortality
- Help physician determine optimal treatment plan and avoid debilitating overtreatment for patients
An EMBL Ventures Portfolio Company
SONETIK
Others
- Hearing aid with novel distribution model
- High quality hearing tests and hearing aids ready to be sold in pharmacies without acoustic specialist consultation
An EMBL Ventures Portfolio Company
Topas therapeutics
Therapeutics
- Liver-targeting peptides that induce antigen-specific immune tolerance, addressing unmet needs in autoimmune, allergies, and anti-drug antibodies.
- Harness the natural mechanisms of the liver to promote immune tolerance to blood borne antigens
- Proprietary Topas Particle Conjugates (TPCs): polymer-cpoated iron oxide nanoparticles conjugated with disease-relevant peptides.
An EMBL Ventures Portfolio Company
Arsanis
Therapeutics
IPO on NASDAQ
- Monoclonal antibody (mAb) immunotherapies for serious infectious diseases
- mAb cocktails that bind bacterial toxins and prevent sepsis in ICU patients
An EMBL Ventures Portfolio Company
viratherapeutics
Therapeutics
Acquired by Boehringer Ingelheim
- Oncolytic viral therapy for cancer treatment
- Produced via proprietary VSV-GP platform: envelope protein reprogramed to be less neurotoxic, less immunogenic, and more efficacious
- Able to administer intravenously instead of intratumorally
An EMBL Ventures Portfolio Company
Luxendo
Enabling Technology
Acquired by Bruker
- Light-sheet fluorescence microscopy instrument for biological samples
- Leverage single-plane illumination microscopy (SPIM) technology to avoid phototoxicity and allow observing fragile living samples for extended periods of time
An EMBL Ventures Portfolio Company
Lipids therapeutics
Therapeutics
- Lipid-based therapies for treating inflammatory diseases of the digestive system